http://www.ncbi.nlm.nih.gov/pubmed/25612744
Abstract
Less
than 8.5% of ischemic stroke patients receive clot-busting drugs within
the narrow time needed to reduce injury. Thus, there is need for an
easily-accessible delayed post-stroke drug treatment to improve
functional recovery. Various combinations of fluoxetine, simvastatin,
and ascorbic acid were given to healthy rats to assess impact on
neurogenesis versus controls. Fluoxetine combined with simvastatin and
ascorbic acid produced a 19-fold increase in neurogenesis versus
controls in healthy rats; fluoxetine alone produced 10-fold increase. We
next tried a couple of drug combinations versus control in
endothelin-induced stroked rats. Combined fluoxetine/
simvastatin/ascorbic acid treatment, given to stroked rats 20-26 hours
after stroke induction and continued for 31 days, produced strong
recovery as measured by Montoya staircase test (mean recovery to 85% of
pre-stroke function) and Forelimb Asymmetry test (mean recovery to 90%
of pre-stroke function). Fluoxetine and ascorbic acid without
simvastatin only produced ~50% of recovery produced by the 3-drug
combination. Our results indicate that combined treatment of Fluoxetine,
simvastatin and ascorbic acid represents a promising delayed stroke
treatment that greatly improves functional recovery in rats and warrants
further study in human patient populations. This work formed the basis
for a patent submission (US20130065924A1) Composition and method for
treatment of neurodegeneration.
- PMID:
- 25612744
- [PubMed - in process]
No comments:
Post a Comment